Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$212.26
+0.1%
$189.84
$153.58
$218.66
$374.91B0.616.09 million shs2.80 million shs
AstraZeneca PLC stock logo
AZN
AstraZeneca
$76.29
+1.0%
$71.42
$62.75
$87.68
$236.61B0.415.68 million shs4.09 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$94.66
+1.4%
$93.75
$81.04
$134.63
$238.96B0.3510.09 million shs10.27 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.58
-0.5%
$26.28
$24.48
$31.54
$144.89B0.6139.66 million shs19.17 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.89%+0.09%+11.30%+22.32%+17.10%
AstraZeneca PLC stock logo
AZN
AstraZeneca
+1.79%-3.07%+4.00%+12.89%+12.12%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-1.28%+0.24%+8.01%-7.73%-23.82%
Pfizer Inc. stock logo
PFE
Pfizer
-1.05%-0.78%-0.54%+1.40%-8.16%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.6601 of 5 stars
2.45.03.33.93.02.51.3
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.4621 of 5 stars
2.63.01.70.03.50.01.3
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.9958 of 5 stars
3.33.04.23.93.83.33.8
Pfizer Inc. stock logo
PFE
Pfizer
4.9761 of 5 stars
3.33.04.24.22.83.33.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.88
Moderate Buy$211.45-0.38% Downside
AstraZeneca PLC stock logo
AZN
AstraZeneca
3.10
Buy$89.7517.64% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.65
Moderate Buy$117.1223.73% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.59
Moderate Buy$31.9224.82% Upside

Current Analyst Ratings Breakdown

Latest AZN, ABBV, MRK, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/5/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$210.00 ➝ $240.00
3/4/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$200.00 ➝ $223.00
2/18/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$128.00 ➝ $105.00
2/13/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
2/12/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
2/12/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $115.00
2/10/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$121.00 ➝ $100.00
2/10/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$121.00 ➝ $100.00
2/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.33B6.65$15.69 per share13.53$1.90 per share111.72
AstraZeneca PLC stock logo
AZN
AstraZeneca
$54.07B4.38$6.47 per share11.79$13.18 per share5.79
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.73$3.28 per share28.82$14.85 per share6.37
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.28$4.01 per share6.38$15.81 per share1.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.4088.4915.181.627.59%296.28%12.65%4/25/2025 (Estimated)
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.2633.7615.261.4213.01%32.23%12.31%4/24/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.7314.069.560.7726.67%45.35%17.36%4/24/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4118.138.440.6412.62%19.47%8.09%4/29/2025 (Estimated)

Latest AZN, ABBV, MRK, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/6/2025Q4 2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.10$1.05-$0.05$0.48$14.19 billionN/A
2/4/2025Q4 2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$1.85$1.72-$0.13$1.48$15.51 billion$15.62 billion
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
1/31/2025Q4 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.98$2.16-$0.82-$0.02$14.81 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.563.09%+6.04%273.33%53 Years
AstraZeneca PLC stock logo
AZN
AstraZeneca
$2.062.70%+1.98%91.15%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.243.42%+5.73%48.14%14 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.73%+2.50%121.99%16 Years

Latest AZN, ABBV, MRK, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/14/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.643.4%4/15/20254/15/20255/15/2025
1/28/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.813.32%3/17/20253/17/20254/7/2025
2/6/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
semi-annual$1.032%2/21/20252/21/20253/24/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
17.94
0.66
0.55
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.65
0.93
0.74
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.79
1.36
1.15
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
55,0001.77 billion1.76 billionOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
89,9003.10 billionN/AOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
69,0002.53 billion2.53 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.67 billion5.66 billionOptionable

Recent News About These Companies

Pfizer Inc. stock logo
Pfizer (NYSE:PFE) Stock Price Up 0.3% - Here's Why
Pfizer Inc. stock logo
Pfizer's (PFE) Buy Rating Reiterated at Guggenheim
Guggenheim Reaffirms Their Buy Rating on Pfizer (PFE)
Pfizer Inc. stock logo
Pfizer (NYSE:PFE) Shares Down 1.5% - Here's Why
Pfizer Inc. stock logo
Guggenheim Reiterates "Buy" Rating for Pfizer (NYSE:PFE)

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbbVie stock logo

AbbVie NYSE:ABBV

$212.26 +0.20 (+0.09%)
As of 01:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$76.29 +0.72 (+0.95%)
As of 01:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$94.66 +1.31 (+1.40%)
As of 01:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer stock logo

Pfizer NYSE:PFE

$25.58 -0.14 (-0.53%)
As of 01:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.